Add To Watchlist
Share URL
Bristol-Myers Squibb Company
BMY: NYSELowest reading is at 36 out of 100. All scores are out of 100.
In Short
About The Company
CEO
Dr. Christopher S. Boerner Ph.D.
Market Cap
128.41 Billion USD
Sector
Healthcare
Website
https://www.bms.comLast Update
28/09/2026, 02:28:05
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Read More
Strongest readings
- ✔Return on capital employed of 16.84% is above the market average of 10.00%
- ✔Share count has been falling at 2.07% per year
- ✔Price-to-earnings of 13.8 is below the market average of 19.6
Weakest readings
- ✘Returns on capital have declined over five years (8.81% lower)
- ✘Debt is high at 2.43 times equity
- ✘Earnings and cashflow growth is weak (growth score 36 out of 100)
- ✘The current price sits above estimated fair value (margin of safety -3.97%)
Key Figures
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Price / earnings (TTM) | 13.83x | 19.60x | |
| ✘ | Margin of safety (DCF) | -3.97% | 17.95% | |
| ✘ | Revenue growth (5y average) | -0.22% | 10.97% | |
| ✔ | Dividend yield (TTM) | 3.97% | 1.85% | |
| ✔ | Share count, per year | -2.07% | 0.00% | |
| ✔ | Return on capital employed | 16.84% | 10.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Valuation
84 / 100Priced at or below the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Price / earnings | 13.83x | 19.60x | |
| ✔ | Free cashflow yield | 8.91% | 4.70% | |
| Price / earnings growth | N/A | 1.50x | ||
| Price / book | 5.75x | — | ||
| ✘ | Margin of safety | -3.97% | 17.95% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Estimated intrinsic value of 60.36 USD is below the current price of 62.86 USD
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Estimated Fair Value: 117.7 USD ✔
Current Price: 62.9 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.
Growth
36 / 100Growing more slowly than the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Revenue growth | -0.22% | 10.97% | |
| ✘ | Earnings growth | 12.46% | 14.48% | |
| ✘ | Cashflow growth | 5.88% | 12.35% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔Revenue growth has improved this year (3.11% against a five year average of -0.22%)
- ✔Earnings growth has improved this year (82.84% against a five year average of 12.46%)
- ✘Free cashflow growth has slowed this year
Health
53 / 100Balance sheet covers its obligations.
Measured on Leverage and capital, Funding and liquidity, Earnings quality.
| Status | Metric | Value | Reading | Threshold |
|---|---|---|---|---|
| ✘ | Altman-Z score | 2.37 | 3.00 | |
| ✔ | Piotroski score | 8.00 | 5.00 | |
| ✘ | Debt / equity | 2.43x | 0.80x | |
| ✔ | Current ratio | 1.26x | 1.00x | |
| ✔ | Interest coverage | 5.93x | 2.50x | |
| ✔ | Free cashflow / debt | 0.29x | 0.15x | |
| ✔ | Debt / capital | 0.71x | 1.00x |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Dividend
62 / 100Covered, with limited headroom.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Dividend yield | 3.97% | 1.85% | |
| ✔ | Dividend growth | 3.74% | 0.00% | |
| ✘ | Payout ratio (earnings) | 54.89% | 40.00% | |
| ✔ | Payout ratio (cashflow) | 44.54% | 65.00% | |
| ✔ | Worst year, last 5 years | 3.39% | -2.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔Dividend growth has been accelerating recently
Management
66 / 100Returns on capital are at or above the market.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Return on equity | 38.19% | 15.00% | |
| ✔ | Return on capital employed | 16.84% | 10.00% | |
| Return on assets | 7.83% | — | ||
| Free cashflow return on capital | 19.28% | — | ||
| ✘ | Return on capital, 5y change | -8.81% | 0.00% | |
| ✔ | Share count, per year | -2.07% | 0.00% | |
| ✘ | Share count, recent | 0.43% | 0.00% | |
| ✘ | Realized buyback return | -32.91% | 0.00% | |
| ✔ | Goodwill erosion / equity | 0.24% | 2.00% | |
| Price volatility, 5 year | 23.46% | — |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔Shares were repurchased while the value score was 84 out of 100
Analysts
not enough data| Status | Metric | Value | Reading | Neutral |
|---|---|---|---|---|
| Analyst opinion score | N/A | 50 |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Financial History
Annual figures across the full reporting history we hold.
Market Peers
BMY
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
See 35+ Years Annual ReportsOther Information
Company Name
Bristol-Myers Squibb Company
Currency
USD
Beta
0.227
Vol Avg
10839782
Ceo
Dr. Christopher S. Boerner Ph.D.
Cik
0000014272
Cusip
Exchange
NYSE
Full Time Employees
32500
Industry
Drug Manufacturers - General
Sector
Healthcare
Ipo Date
Address
Route 206 & Province Line Road
City
Princeton
State
NJ
Country
United States
Zip
08543
Phone
609 252 4621
Analysis Last Updated
28/09/2026, 02:28:05
Financial data compiled from SEC EDGAR filings and Yahoo Finance.